Overview

Oligonucleotide API Market is poised to value USD 4406 million by 2028 end at a CAGR of 10.2% during the forecast period 2022 to 2028. 

Oligonucleotides are a novel form of pharmaceutical molecule that can be utilised to treat a variety of diseases. They're little strands of altered DNA, around 20 nucleotides long. The most common process for generating oligonucleotides is to isolate the active pharmaceutical ingredient (API) by lyophilization to make a solid product, which is then dissolved to produce an aqueous formulation.

Oligonucleotide active pharmaceutical ingredients (APIs) have previously been utilised in solid solutions (powdered form) and, more recently, in solution form. The oligonucleotide active pharmaceutical ingredient (API) sector is being driven by the widespread usage of oligonucleotide active pharmaceutical ingredients in the treatment of various illnesses. Product development has cleared the way for novel therapeutic procedures in a variety of fields, including ophthalmology, neuromuscular diseases, and vaccine adjuvants.

Some of the most significant oligonucleotide classes include micro-RNA, small/short interfering RNA, antisense oligonucleotides, immunostimulatory oligonucleotides, aptamers, and splice-switching oligonucleotides. Some of the characteristics that have boosted the trend of oligonucleotide APIs in solution include solution stability, viscosity, concentration, end-to-end production, and packaging.

Because of major breakthroughs made in industry associations regarding CMC (chemistry, manufacturing, and control) methodologies, the market for oligonucleotide APIs is looking brighter. The market for innovative medication classes for chronic obstructive pulmonary disease and asthma is expanding, creating new opportunities.

FutureWise Market Research has instantiated a report that provides an intricate analysis of Oligonucleotide API Market  trends that shall affect the overall market growth. Furthermore, it includes detailed information on the graph of profitability, SWOT analysis, market share and regional proliferation of this business. Moreover, the report offers insights on the current stature of prominent market players in the competitive landscape analysis of this market.

According to the research study conducted by FutureWise research analysts, the Oligonucleotide API Market is anticipated to attain substantial growth by the end of the forecast period. The report explains that this business is predicted to register a noteworthy growth rate over the forecast period. This report provides crucial information pertaining to the total valuation that is presently held by this industry and it also lists the segmentation of the market along with the growth opportunities present across this business vertical.

Major players included in the Oligonucleotide API Market:
• Agilent Technologies, Inc.
• Bachem Holding AG
• CordenPharma International
• Integrated DNA Technologies, Inc. (Danaher Corporation)
• Eurofins Scientific
• GE Healthcare
• Merck KGaA
• Thermo Fisher Scientific
• RiBoBio Co.
• LGC Biosearch Technologies
• ST Pharm
• Kaneka Eurogentec S.A.
• Ajinomoto Co., Inc.
• Bio-synthesis Inc.
• STA Pharmaceutical Co., Ltd.
• BioSpring GmbH
(Note: The list of the major players will be updated with the latest market scenario and trends)

Oligonucleotide API Market Segmentation:
By API Type
• Antisense Oligonucleotides API
• Short Interfering RNA (siRNA) API
• Phosphorodiamidate Morpholino Oligonucleotides (PMO) API
• MiRNA API
• Aptamers API
• CpG Oligonucleotides API
• Others (ON Conjugates (NP), ShRNA, etc.)
By Marketing Status
• Marketed
• Clinical Trials (Clinical Phases)
By End User
• Contract Manufacturing Organizations (CMOs)
• Pharmaceutical Companies
• Biopharmaceutical Companies
• Contract Development & Manufacturing Organizations (CDMOs)
By Region
• North America
• Europe
• Asia-Pacific
• Latin America
• Middle East and Africa

Oligonucleotide API Market Sample Video:

Competitive Landscape:
• Tier 1 players- established companies in the market with a major market share
• Tier 2 players
• Emerging players which are growing rapidly
• New Entrants

FutureWise Key Takeaways:
• Growth prospects
• SWOT analysis
• Key trends
• Key data-points affecting market growth

Objectives of the Study:
• To provide with an exhaustive analysis on the Oligonucleotide API Market By API Type, By Marketing Status, By End User and By Region.
• To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints)
• To evaluate and forecast micro-markets and the overall market
• To predict the market size, in key regions— North America, Europe, Asia Pacific, Latin America and Middle East and Africa.
• To record and evaluate competitive landscape mapping- product launches, technological advancements, mergers and expansions

Flexible Delivery Model:
• We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement
• The customization Mobility Care offered are free of charge with purchase of any license of the report
• You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com

Table of Contents

1. Market Introduction
  1.1 Objectives of the Study
  1.2 Market Definition
  1.3 Market Scope
      1.3.1 Years Considered for the Study
      1.3.2 Market Covered
  1.4 Currency
  1.5 Limitations
  1.6 Stakeholders

2. Research Methodology
   2.1 Research Data
       2.1.1 Secondary Data
             2.1.1.1 Key Data from Secondary Sources
       2.1.2 Primary Data
             2.1.2.1 Key Data from Primary Sources
   2.2 Market Size Estimation
   2.3 Market Breakdown and Data Triangulation
   2.4 Assumptions for the Study  

3. Executive Summary
  3.1 Market Outlook
  3.2 Segment Outlook
  3.3 Competitive Insights

4. Oligonucleotide API Market  Variables, Trends & Scope
  4.1. Market Lineage Outlook
  4.2. Penetration and Growth Prospect Mapping
  4.3. Industry Value Chain Analysis
  4.4. Cost Analysis Breakdown
  4.5. Technology Overview
  4.6. Regulatory Framework
       4.6.1. Reimbursement Framework
       4.6.2. Standards and Compliances

5. Market Overview
  5.1. Market Dynamics
       5.1.1. Market Driver Analysis
              5.1.1.1. Increasing focus of Oligonucleotide API Market  Companies on Brand Protection
              5.1.1.2. Untapped Opportunities in Emerging Regions
       5.1.2. Market Restraint Analysis
              5.1.2.1. High Cost Associated with Implementation of Predictive Analysis
       5.1.3. Industry Challenges
              5.1.3.1. Presence of Ambiguous Regulatory Framework

6. Oligonucleotide API Market  Analysis Tools
  6.1. Industry Analysis - Porter’s
       6.1.1. Supplier Power
       6.1.2. Buyer Power
       6.1.3. Substitution Threat
       6.1.4. Threat from New Entrants
       6.1.5. Competitive Rivalry
  6.2. Pestel Analysis
       6.2.1. Political Landscape
       6.2.2. Environmental Landscape
       6.2.3. Social Landscape
       6.2.4. Technology Landscape
       6.2.5. Legal Landscape
  6.3. Major Deals And Strategic Alliances Analysis
       6.3.1. Joint Ventures
       6.3.2. Mergers and Acquisitions
       6.3.3. Licensing and Partnership
       6.3.4. Technology Collaborations
       6.3.5. Strategic Divestments
  6.4. Market Entry Strategies
  6.5. Case Studies

7. Oligonucleotide API Market, By API Type Historical Analysis and Forecast 2022-2028 (USD Million)
  7.1. Antisense Oligonucleotides API
  7.2. Short Interfering RNA (siRNA) API
  7.3. Phosphorodiamidate Morpholino Oligonucleotides (PMO) API
  7.4. MiRNA API
  7.5. Aptamers API
  7.6. CpG Oligonucleotides API
  7.7. Others (ON Conjugates (NP), ShRNA, etc.)

8. Oligonucleotide API Market, By Marketing Status Historical Analysis and Forecast 2022-2028 (USD Million)
  8.1. Marketed
  8.2. Clinical Trials (Clinical Phases)

9. Oligonucleotide API Market, By End User Historical Analysis and Forecast 2022-2028 (USD Million)
  9.1. Contract Manufacturing Organizations (CMOs)
  9.2. Pharmaceutical Companies
  9.3. Biopharmaceutical Companies
  9.4. Contract Development & Manufacturing Organizations (CDMOs)

10. North America Oligonucleotide API Market Analysis 2016–2020 and Forecast 2022–2028 (USD Million)
  10.1. Introduction
  10.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020
       10.2.1. U.S.A
       10.2.2. Canada
       10.2.3. Mexico
  10.3. Market Size (USD Million) Forecast for North America 2022-2028

11. Latin America Oligonucleotide API Market Analysis 2016–2020 and Forecast 2022–2028 (USD Million)
   11.1. Introduction
   11.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020
         11.2.1. Brazil
         11.2.2. Venezuela
         11.2.3. Argentina
         11.2.4. Rest of Latin America
   11.3. Market Size (USD Million) Forecast for Latin America 2022-2028

12. Europe Oligonucleotide API Market Analysis 2016–2020 and Forecast 2022–2028 (USD Million)
   12.1. Introduction
   12.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020
         12.2.1. Germany
         12.2.2. U.K        
         12.2.3. France
         12.2.4. Italy
         12.2.5. Spain
         12.2.6. Russia
         12.2.7. Poland
         12.2.8. Rest of Europe
   12.3. Market Size (USD Million) Forecast for Europe 2022-2028

13. Asia Pacific Oligonucleotide API Market Analysis 2016–2020 and Forecast 2022–2028 (USD Million)
   13.1. Introduction
   13.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020
         13.2.1. Japan
         13.2.2. China
         13.2.3. India
         13.2.4. Australia and New Zealand
         13.2.5. ASEAN
         13.2.6. Rest of Asia Pacific
   13.3. Market Size (USD Million) Forecast for Asia Pacific 2022-2028  

14. Middle East and Africa Market Analysis 2016–2020 and Forecast 2022–2028 (USD Million)
   14.1. Introduction
   14.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020
         14.2.1. GCC
         14.2.2. Israel
         14.2.3. South Africa
         14.2.4. Rest of MEA
   14.3. Market Size (USD Million) Forecast for MEA 2022-2028

15. Market Share Analysis and Competitive Landscape  
   15.1. Global Landscape - Key Players, Revenue and Presence
   15.2. Global Share Analysis - Key Players (Tier 1, Tier 2, Tier 3)
   15.3. Global Emerging Companies
   15.4.  North America - Market Share Analysis and Key Regional Players
   15.5.  Europe - Market Share Analysis and Key Regional Players
   15.6.  Asia Pacific - Market Share Analysis and Key Regional Players
   15.7.  Global Key Player - Growth Matrix

16. Company Profiles (Competition Dashboard, Competitors Deep Dive, Products Offered and Financial Layouts)
   16.1. Agilent Technologies, Inc.
         16.1.1. Company Overview
         16.1.2. Product Portfolio
         16.1.3. SWOT Analysis
         16.1.4. Financial Overview
         16.1.5. Strategic Overview
   16.2. Bachem Holding AG
         16.2.1. Company Overview
         16.2.2. Product Portfolio
         16.2.3. SWOT Analysis
         16.2.4. Financial Overview
         16.2.5. Strategic Overview
   16.3. CordenPharma International
         16.3.1. Company Overview
         16.3.2. Product Portfolio
         16.3.3. SWOT Analysis
         16.3.4. Financial Overview
         16.3.5. Strategic Overview
   16.4. Integrated DNA Technologies, Inc. (Danaher Corporation)
         16.4.1. Company Overview
         16.4.2. Product Portfolio
         16.4.3. SWOT Analysis
         16.4.4. Financial Overview
         16.4.5. Strategic Overview
   16.5 Eurofins Scientific
         16.5.1. Company Overview
         16.5.2. Product Portfolio
         16.5.3. SWOT Analysis
         16.5.4. Financial Overview
         16.5.5. Strategic Overview          
   16.6 GE Healthcare
         16.6.1. Company Overview
         16.6.2. Product Portfolio
         16.6.3. SWOT Analysis
         16.6.4. Financial Overview
         16.6.5. Strategic Overview      
   16.7. Merck KGaA
         16.7.1. Company Overview
         16.7.2. Product Portfolio
         16.7.3. SWOT Analysis
         16.7.4. Financial Overview
         16.7.5. Strategic Overview
   16.8. Thermo Fisher Scientific
         16.8.1. Company Overview
         16.8.2. Product Portfolio
         16.8.3. SWOT Analysis
         16.8.4. Financial Overview
         16.8.5. Strategic Overview
   16.9. RiBoBio Co.
         16.9.1. Company Overview
         16.9.2. Product Portfolio
         16.9.3. SWOT Analysis
         16.9.4. Financial Overview
         16.9.5. Strategic Overview
   16.10. LGC Biosearch Technologies
         16.10.1. Company Overview
         16.10.2. Product Portfolio
         16.10.3. SWOT Analysis
         16.10.4. Financial Overview
         16.10.5. Strategic Overview
   16.11. ST Pharm
         16.11.1. Company Overview
         16.11.2. Product Portfolio
         16.11.3. SWOT Analysis
         16.11.4. Financial Overview
         16.11.5. Strategic Overview
   16.12. Kaneka Eurogentec S.A.
         16.12.1. Company Overview
         16.12.2. Product Portfolio
         16.12.3. SWOT Analysis
         16.12.4. Financial Overview
         16.12.5. Strategic Overview
   16.13. Ajinomoto Co., Inc.
         16.13.1. Company Overview
         16.13.2. Product Portfolio
         16.13.3. SWOT Analysis
         16.13.4. Financial Overview
         16.13.5. Strategic Overview
   16.14. Bio-synthesis Inc.
         16.14.1. Company Overview
         16.14.2. Product Portfolio
         16.14.3. SWOT Analysis
         16.14.4. Financial Overview
         16.14.5. Strategic Overview
   16.15. STA Pharmaceutical Co., Ltd.
         16.15.1. Company Overview
         16.15.2. Product Portfolio
         16.15.3. SWOT Analysis
         16.15.4. Financial Overview
         16.15.5. Strategic Overview
   16.16. BioSpring GmbH
         16.16.1. Company Overview
         16.16.2. Product Portfolio
         16.16.3. SWOT Analysis
         16.16.4. Financial Overview
         16.16.5. Strategic Overview

17. Pre and Post COVID-19 Impact
   17.1. Positive influence on the healthcare industry
   17.2. The financial disruption of the manufacturing sector
   17.3. Impact of COVID-19 on emerging companies
   17.4. Significant mandates in the healthcare regulations initiated by administrations
   17.5. The overall economic slowdown of the developing and developed nations

18. FutureWise SME Key Takeaway Points for Client

Tables

Figures